Tokushima

Futó vizsgálatok

• Toboroz

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· 3. fázis· Forrás

• Toboroz

  Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

  NCT06357533· 3. fázis· Forrás

• Fut, nem toboroz

  Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

  NCT05301842· 3. fázis· Forrás

• Fut, nem toboroz

  A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

  NCT05221840· 3. fázis· Forrás

• Fut, nem toboroz

  SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)

  NCT05141201· Forrás

• Fut, nem toboroz

  Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

  NCT03703297· 3. fázis· Forrás

• Fut, nem toboroz

  Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

  NCT03043872· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

  NCT02542293· 3. fázis· Forrás

• Fut, nem toboroz

  Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

  NCT02453282· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Szívelégtelenség1 toboroz
• Tüdőrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Forxiga CKD Japan Post-Marketing Surveillance (PMS)

  NCT05306210· Forrás

• Lezárult

  Forxiga HF General Drug Use-Results Study

  NCT04865406· Forrás

• Lezárult

  Durvalumab Long-Term Safety and Efficacy Study

  NCT04078152· 4. fázis· Forrás

• Lezárult

  Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC

  NCT03995875· Forrás